Gastrografin for Small Bowel Obstruction

Children's Hospital, London Health Sciences Centre, London, Canada
Small Bowel ObstructionGastrografin - Drug
Eligibility
6 - 18
All Sexes

Study Summary

This trial is testing whether adding Gastrografin to standard non-surgical management of small bowel obstruction is effective.

Eligible Conditions
  • Small Bowel Obstruction

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2 & 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Through study completion, up to 6 months

Month 6
Length of hospital stay
Rate of complications
Time to first feed
Time to full feeds
rate of surgical intervention

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

2 Treatment Groups

Control Arm
1 of 2
Gastrografin Arm
1 of 2

Experimental Treatment

146 Total Participants · 2 Treatment Groups

Primary Treatment: Gastrografin · No Placebo Group · Phase 2 & 3

Control Arm
Other
Experimental Group · 1 Intervention: Saline solution (control treatment) · Intervention Types: Other
Gastrografin Arm
Drug
Experimental Group · 1 Intervention: Gastrografin · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, up to 6 months

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
629 Previous Clinical Trials
403,831 Total Patients Enrolled

Eligibility Criteria

Age 6 - 18 · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

Why is Gastrografin given to patients?

"Gastrografin is an effective agent for retrograde cystourethrography, arteriography, and computerized tomography." - Anonymous Online Contributor

Unverified Answer

Are there any open positions in this trial for willing participants?

"That is accurate. According to the information available on clinicaltrials.gov, this trial was posted on September 1st, 2019 and is currently recruiting patients. The study plans to admit a total of 146 participants from one site." - Anonymous Online Contributor

Unverified Answer

Does this research include patients who are octogenarians or above?

"Children aged 6 months to 18 years old may qualify for this particular trial, though there are other studies more suited for different age groups. For example, there are 3 trials specifically designed for those under 18 and 13 trials investigating treatments for seniors above the age of 65." - Anonymous Online Contributor

Unverified Answer

What is the research history of Gastrografin?

"Currently, there is 1 trial studying Gastrografin that is in Phase 3. Out of the total trials for Gastrografin, most are located in London, Ontario with one other location running a study." - Anonymous Online Contributor

Unverified Answer

How many people are partaking in this clinical trial at most?

"That is accurate. The listing on clinicaltrials.gov says that the research team is still looking for participants. This study was first made public on September 1st, 2019 and had new information added as recently as April 5th, 2022. So far, 146 people have signed up to take part in this experiment at a single location." - Anonymous Online Contributor

Unverified Answer

Could I possibly join this clinical trial?

"Eligible patients for this trial must have intestinal obstruction and be between 6 months old to 18 years old. The study is looking to enroll 146 participants in total." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.